GlassScriptPhysician profile
Uzair Amjad
NPI 1467039065
$2,924.12
in general payments reported to CMS, 2019-2025
10 companies · $2,415 in 2025
The $2,415 reported for 2025 was more than what 86% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $179 · 2024: $330 · 2025: $2,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969 · Long Term Medical Supply Or Device Loan: $516 · Travel and Lodging: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.28 |
| Long Term Medical Supply Or Device Loan | $516.39 |
| Travel and Lodging | $438.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $1,062.05 | 2025 | |
| Integra Lifesciences Corporation | $842.18 | 2024-2025 | Integra, Amnioexcel Plus, Integra Dermal Regeneration Template |
| Smith+Nephew, INC. | $582.11 | 2023-2025 | Bone Anchors With Arthroscopic Delivery System, Stravix, Panta 2 |
| Orthofix Medical, INC. | $248.38 | 2025 | Truelok, Tl-Hex Truelok Hexapod System |
| Bioventus LLC | $85.16 | 2024 | Exogen Ultrasound Bone Healing System |
| Depuy Synthes Sales INC. | $27.30 | 2024 | Na |
| Aroa Biosurgery Incorporated | $25.68 | 2025 | |
| Paratek Pharmaceuticals, INC. | $20.64 | 2024 | Nuzyra |
| Stryker Corporation | $19.86 | 2025 | N/A |
| Kerecis Limited | $10.76 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzair Amjad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.